<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Definition, risk factors, and evaluation of resistant hypertension</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Definition, risk factors, and evaluation of resistant hypertension</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Definition, risk factors, and evaluation of resistant hypertension</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Raymond R Townsend, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">George L Bakris, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William B White, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John P Forman, MD, MSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 08, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Patients with persistent hypertension despite multiple medications are at high risk for adverse cardiovascular events and are more likely than those with controlled hypertension to have a secondary (ie, identifiable) cause, which is usually at least in part reversible.</p><p>The definition, prevalence, risk factors, and evaluation of resistant hypertension will be reviewed here. Specific causes of secondary hypertension will be briefly mentioned. The treatment and prognosis of resistant hypertension, indications for referral to a hypertension specialist, and how one identifies patients who should be screened for secondary hypertension are discussed elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3819.html" rel="external">"Treatment of resistant hypertension"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3862.html" rel="external">"Evaluation of secondary hypertension"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph utd-adt-cnt utd-adt-pathwys">●</span><span class="utd-adt-cnt utd-adt-pathwys utd-content-127445">(Related Pathway(s):  <a class="utd-content-127445" href="/pathway/127445?topicRef=3818&amp;source=see_link">Evaluation of adults with apparent resistant hypertension</a>.)</span></p><p></p><p class="headingAnchor" id="H2"><span class="h1">DEFINITIONS</span></p><p class="headingAnchor" id="H3"><span class="h2">Resistant hypertension</span><span class="headingEndMark"> — </span>Resistant hypertension is defined by the 2018 American Heart Association (AHA) scientific statement, by the 2017 American College of Cardiology (ACC)/AHA hypertension guideline, and by the 2018 European Society of Cardiology and European Society of Hypertension (ESC/ESH) statement as blood pressure that remains above goal in spite of concurrent use of three antihypertensive agents of different classes [<a href="#rid1">1-3</a>]. If tolerated, one of the three agents should be a diuretic, and all agents should be prescribed at maximum recommended (or maximally tolerated) antihypertensive doses [<a href="#rid1">1</a>]. Patients whose blood pressure is controlled with four or more medications should also be considered to have resistant hypertension.</p><p>Goal blood pressure is presented separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3861.html" rel="external">"Goal blood pressure in adults with hypertension"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3823.html" rel="external">"Antihypertensive therapy for secondary stroke prevention"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3829.html" rel="external">"Treatment of hypertension in patients with diabetes mellitus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7169.html" rel="external">"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults", section on 'Blood pressure goal'</a>.)</p><p></p><p>The preceding criteria define a patient who has <strong>apparent</strong> resistant hypertension. Among patients with apparent resistance, true resistant hypertension is distinguished from pseudoresistance by confirming that blood pressure is above goal when measured in the office using proper technique  (<a class="graphic graphic_table graphicRef115862" href="/d/graphic/115862.html" rel="external">table 1</a>), by then confirming uncontrolled hypertension with out-of-office measurements (ie, ambulatory blood pressure monitoring or home blood pressure monitoring), and by considering and excluding nonadherence to antihypertensive therapy  (<a class="graphic graphic_algorithm graphicRef127818" href="/d/graphic/127818.html" rel="external">algorithm 1</a>) [<a href="#rid1">1</a>]. (See <a class="local">'Apparent, true, and pseudoresistant hypertension'</a> below.)</p><p>Although patients with resistant hypertension may have elevations in both systolic and diastolic pressures, isolated systolic hypertension is common. In the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) of over 33,000 hypertensive patients treated with different antihypertensive drugs, only 67 percent of participants attained a systolic blood pressure below 140 mmHg, whereas 92 percent attained a diastolic pressure below 90 mmHg [<a href="#rid4">4</a>]. Treatment of older adults with isolated systolic hypertension that is resistant to therapy may be more difficult since intensification of the therapeutic regimen may lead to unacceptably low diastolic pressures. (See  <a class="medical medical_review" href="/d/html/3863.html" rel="external">"Treatment of hypertension in older adults, particularly isolated systolic hypertension", section on 'Resistant hypertension'</a> and  <a class="medical medical_review" href="/d/html/3863.html" rel="external">"Treatment of hypertension in older adults, particularly isolated systolic hypertension"</a>.)</p><p>Resistant hypertension is <strong>not</strong> synonymous with uncontrolled hypertension since resistant hypertension is not the only cause of uncontrolled hypertension. Other causes include inadequate treatment regimens and pseudoresistance. (See <a class="local">'Apparent, true, and pseudoresistant hypertension'</a> below.)</p><p class="headingAnchor" id="H2761182"><span class="h3">Refractory hypertension</span><span class="headingEndMark"> — </span>Some patients with resistant hypertension cannot be controlled, even with maximal medical therapy (five or more drugs including <a class="drug drug_general" data-topicid="9255" href="/d/drug information/9255.html" rel="external">chlorthalidone</a> and a mineralocorticoid receptor antagonist) under the care of a hypertension specialist. Such patients are referred to as having <strong>refractory hypertension </strong>[<a href="#rid5">5</a>]. The prevalence and characteristics of refractory hypertension were evaluated in a cohort of more than 550 patients with confirmed (true) resistant hypertension referred to a specialized hypertension clinic [<a href="#rid6">6</a>]. Refractory hypertension was defined as the inability to achieve blood pressure control (by office or ambulatory blood pressure monitoring) despite maximum tolerated doses of at least five antihypertensive medications, including chlorthalidone and <a class="drug drug_general" data-topicid="9943" href="/d/drug information/9943.html" rel="external">spironolactone</a>. The patients with refractory hypertension (approximately 3 percent of those with resistant hypertension) achieved a mean office blood pressure of 178/103 mmHg despite an average of six antihypertensive medications. Compared with patients who had controlled resistant hypertension, those with refractory hypertension had significantly higher heart rates (78 versus 69 beats per minute despite more beta blocker use) and higher systemic vascular resistance (despite greater use of vasodilators).</p><p>Based upon the persistently higher heart rates and lack of response to intensive diuretic therapy among patients with refractory hypertension, the authors suggested that treatment failure in such patients may be due to neurologic mechanisms (eg, sympathetic overactivity). This contrasts with the conventional thinking that resistant hypertension is largely due to persistent extracellular fluid volume expansion.</p><p class="headingAnchor" id="H4"><span class="h2">Apparent, true, and pseudoresistant hypertension</span><span class="headingEndMark"> — </span>In patients who appear to have resistant hypertension according to the definition presented above, it should be determined whether the hypertension is truly resistant  (<a class="graphic graphic_algorithm graphicRef127818" href="/d/graphic/127818.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Apparent resistant hypertension</strong> – Patients with apparent resistant hypertension have uncontrolled clinic blood pressure despite being <strong>prescribed</strong> three or more antihypertensive medications or require prescriptions of four or more drugs to control their blood pressure [<a href="#rid7">7,8</a>]. However, such patients may have pseudoresistant hypertension.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>True resistant hypertension</strong> – Patients with true resistant hypertension are those who have uncontrolled clinic blood pressure despite being adherent to an antihypertensive regimen that includes three or more drugs (including a diuretic, and each at optimal doses) and who also have uncontrolled blood pressure confirmed by 24-hour ambulatory blood pressure monitoring. The prevalence of true resistant hypertension was assessed in 140 patients with uncontrolled clinic blood pressure who were participating in a randomized trial [<a href="#rid9">9</a>]. Of these patients, 69 were prescribed at least three different antihypertensive medications. However, 15 (22 percent) of these patients with apparent resistant hypertension had normal 24-hour ambulatory blood pressure, 20 patients (29 percent) were nonadherent to therapy, and 3 patients (4 percent) were not prescribed a diuretic. Thus, only 31 (45 percent) of the patients with apparent resistant hypertension had true resistant hypertension. In addition, none of the patients taking a diuretic in this study were taking <a class="drug drug_general" data-topicid="9255" href="/d/drug information/9255.html" rel="external">chlorthalidone</a>, the preferred diuretic, and none were taking <a class="drug drug_general" data-topicid="9943" href="/d/drug information/9943.html" rel="external">spironolactone</a>, which is effective in patients with resistant hypertension. (See  <a class="medical medical_review" href="/d/html/3819.html" rel="external">"Treatment of resistant hypertension"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pseudoresistant hypertension</strong> – Pseudoresistance refers to poorly-controlled hypertension that appears resistant to treatment but is actually attributable to other factors. The five most common causes of pseudoresistance are:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Inaccurate measurement of blood pressure (eg, use of an inappropriately small blood pressure cuff). (See  <a class="medical medical_review" href="/d/html/3879.html" rel="external">"Blood pressure measurement in the diagnosis and management of hypertension in adults"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Poor adherence to antihypertensive therapy. Adherence to prescribed antihypertensive therapy in a large cohort of patients with resistant hypertension was determined by performing mass spectrometry of blood samples collected from participants enrolled in a trial of renal denervation [<a href="#rid10">10</a>]. Complete nonadherence or poor adherence was detected in 80 percent of all patients. Overall, participants took an average of two antihypertensive medications despite being prescribed an average of four medications.</p><p></p><p class="bulletIndent2">The importance of nonadherence to antihypertensive medications in resistant or refractory hypertension has also been identified in other studies. In one study, for example, 40 out of 76 patients with unexplained resistance to four or more antihypertensive drugs were determined to be either nonadherent or only partially adherent to therapy [<a href="#rid11">11</a>]. In another study, 29 of 83 patients (35 percent) who had hypertension resistant to an average of four antihypertensive medications or who were referred for renal denervation were found to be nonadherent or only partially adherent when their urine was screened for antihypertensive drugs using liquid chromatography and mass spectrometry [<a href="#rid12">12</a>]. Similarly, in a cohort of patients with apparent refractory hypertension, approximately 50 percent were taking five or more antihypertensive drugs [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/d/html/3845.html" rel="external">"Patient adherence and the treatment of hypertension"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Suboptimal antihypertensive therapy. Among 468,877 patients included in an outpatient network, 44,684 (9.5 percent) had apparent resistant hypertension [<a href="#rid7">7</a>]. Of these, however, only 22,189 (one-half of those with apparent resistant hypertension) were prescribed optimal antihypertensive therapy (defined as a diuretic and two or more additional drugs, each at 50 percent or more of the maximal recommended antihypertensive dose). (See  <a class="medical medical_review" href="/d/html/3819.html" rel="external">"Treatment of resistant hypertension"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Poor adherence to lifestyle and dietary approaches to lower blood pressure, such as a reduced sodium intake. (See <a class="local">'Lifestyle and diet'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>White coat hypertension. (See <a class="local">'White coat effect'</a> below.)</p><p></p><p class="headingAnchor" id="H5"><span class="h3">White coat effect</span><span class="headingEndMark"> — </span>White coat effect refers to patients with treated hypertension who have office readings that average more than 130/80 mmHg and <strong>reliable</strong> out-of-office readings that average less than 130/80 mmHg [<a href="#rid2">2</a>]. Having the blood pressure in the office taken by a nurse or technician, rather than the clinician, may minimize the white coat effect  (<a class="graphic graphic_figure graphicRef73781" href="/d/graphic/73781.html" rel="external">figure 1</a>).</p><p>White coat hypertension is present in as many as 20 to 30 percent of patients, possibly leading to an erroneous diagnosis of either hypertension or, in a patient with known hypertension, resistant disease. White coat effect is more common among patients with resistant hypertension, with a reported prevalence of 37 to 44 percent in four studies [<a href="#rid14">14-17</a>]. (See  <a class="medical medical_review" href="/d/html/3820.html" rel="external">"Out-of-office blood pressure measurement: Ambulatory and self-measured blood pressure monitoring"</a>.)</p><p>Patients with white coat effect have less severe target-organ damage and appear to be at less cardiovascular risk compared with those patients with persistent hypertension during ambulatory monitoring [<a href="#rid14">14-16,18</a>]. (See <a class="local">'Ambulatory and home blood pressure monitoring'</a> below.)</p><p class="headingAnchor" id="H6"><span class="h1">PREVALENCE</span><span class="headingEndMark"> — </span>The prevalence of true resistant hypertension is not known. A major problem is that not all patients with uncontrolled hypertension have resistant hypertension as defined above. Many are uncontrolled because of poor adherence or inadequate treatment regimens. (See <a class="local">'Resistant hypertension'</a> above.)</p><p>In an unselected, population-based sample of 15,968 adults in the United States, the prevalence of apparent resistant hypertension was 8.9 percent among all individuals with hypertension (defined as a blood pressure ≥140 mmHg systolic or ≥90 mmHg diastolic) and 12.8 percent among those treated with antihypertensive medications [<a href="#rid19">19</a>]. In selected populations of hypertensive patients who seek medical care, the prevalence may be higher, ranging from 12.3 percent in Spain to 16 percent in the southeastern United States when defining hypertension as ≥140/≥90 mmHg [<a href="#rid14">14,19-22</a>]. The prevalence was substantially lower in several other studies [<a href="#rid23">23,24</a>]. As an example, in a study of 205,570 patients newly diagnosed with hypertension and followed at a large health maintenance organization, only 2 percent remained treatment resistant after 1.5 years of follow-up [<a href="#rid23">23</a>].</p><p>An analysis of antihypertensive medication prescriptions written in the United States suggested that the prevalence of more difficult-to-control hypertension is increasing [<a href="#rid25">25</a>]. The proportion of hypertensive patients receiving three or more blood pressure medications increased from 14 to 24 percent between 1994 and 2004. Possible reasons for the increase in difficult-to-control hypertension include increases in the average age and the average weight of the population. Data were not given on resistant hypertension.</p><p class="headingAnchor" id="H7"><span class="h1">RISK FACTORS</span><span class="headingEndMark"> — </span>Patient characteristics that predict difficult-to-control hypertension include higher baseline blood pressure (particularly systolic), presence of left ventricular hypertrophy (especially by echocardiogram), older age, obesity, chronic kidney disease, and diabetes [<a href="#rid17">17,24,26</a>].</p><p>Potentially reversible factors that contribute to resistant hypertension include suboptimal therapy, lifestyle and diet, medications and herbal preparations that can raise the blood pressure, and secondary causes of hypertension.</p><p class="headingAnchor" id="H8"><span class="h2">Suboptimal therapy</span><span class="headingEndMark"> — </span>Suboptimal therapy is a common cause of apparent resistant hypertension [<a href="#rid1">1</a>]. It is most often due to the lack of administration of more effective drugs and failure to prevent volume expansion with adequate diuretic therapy [<a href="#rid27">27-29</a>] (see <a class="local">'Extracellular volume expansion'</a> below). In one report, only 18 and 27 percent of patients with uncontrolled hypertension were treated with at least three antihypertensive drugs (one of which being a diuretic) by general practitioners and cardiologists, respectively [<a href="#rid28">28</a>].</p><p class="headingAnchor" id="H9"><span class="h2">Lifestyle and diet</span><span class="headingEndMark"> — </span>Obesity, a high-salt diet, physical inactivity, and heavy alcohol intake all contribute to hypertension, although not all have been examined specifically among patients with resistant hypertension.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3875.html" rel="external">"Overweight, obesity, and weight reduction in hypertension"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3877.html" rel="external">"Salt intake and hypertension"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3828.html" rel="external">"Exercise in the treatment and prevention of hypertension"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2784.html" rel="external">"Cardiovascular benefits and risks of moderate alcohol consumption", section on 'Hypertension'</a>.)</p><p></p><p>The contribution of dietary salt to resistant hypertension was examined in a randomized trial in which 12 patients with resistant hypertension were assigned to a low- (50 mEq/day) or high- (250 mEq/day) sodium diet for one week [<a href="#rid30">30</a>]. After a two-week washout, the patients received the other diet. Switching from the high- to low-salt diet was associated with an average reduction in office blood pressure of 23/9 mmHg and a reduction in the 24-hour ambulatory blood pressure of 20/10 mmHg.</p><p class="headingAnchor" id="H10"><span class="h2">Medications</span><span class="headingEndMark"> — </span>A variety of medications can raise the blood pressure and, in some cases, reduce the response to antihypertensive drugs [<a href="#rid1">1-3</a>]. The most commonly implicated agents are over-the-counter and prescribed medications, including nonsteroidal antiinflammatory drugs (NSAIDs), including some but not all (eg, <a class="drug drug_general" data-topicid="8847" href="/d/drug information/8847.html" rel="external">celecoxib</a>) of the selective cyclooxygenase-2 (COX-2) inhibitors  (<a class="graphic graphic_table graphicRef56767" href="/d/graphic/56767.html" rel="external">table 2</a>) [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/d/html/7968.html" rel="external">"NSAIDs: Adverse cardiovascular effects"</a>.)</p><p>The NSAIDs that raise blood pressure can interfere with the antihypertensive effect of virtually any agent except calcium channel blockers [<a href="#rid28">28</a>]. A presumed mechanism by which the blood pressure rises is a reduction in sodium excretion, thereby increasing the intravascular volume. (See  <a class="medical medical_review" href="/d/html/2385.html" rel="external">"NSAIDs and acetaminophen: Effects on blood pressure and hypertension"</a>.)</p><p>Other agents that may contribute to hypertension include sympathomimetics (diet pills, decongestants, amphetamine-like stimulants), glucocorticoids, herbal preparations, estrogen-containing contraceptives, calcineurin inhibitors, and antidepressants [<a href="#rid32">32-35</a>]. (See  <a class="medical medical_review" href="/d/html/3827.html" rel="external">"Contraception: Hormonal contraception and blood pressure"</a> and  <a class="medical medical_review" href="/d/html/7995.html" rel="external">"Pharmacology of cyclosporine and tacrolimus"</a>.)</p><p class="headingAnchor" id="H11"><span class="h2">Extracellular volume expansion</span><span class="headingEndMark"> — </span>Relative or absolute volume expansion is frequently at least partially responsible for an inability to control hypertension [<a href="#rid36">36,37</a>]. Underlying kidney function impairment, sodium retention due to therapy with vasodilators, and/or ingestion of a high-salt diet (which can be assessed by measuring sodium excretion in a 24-hour urine collection) all may play a role.</p><p class="headingAnchor" id="H12"><span class="h2">Secondary causes of hypertension</span><span class="headingEndMark"> — </span>Patients with resistant hypertension are much more likely to have an identifiable cause of hypertension (ie, secondary hypertension) [<a href="#rid1">1,33,37</a>]. As an example, of the 1416 patients with resistant hypertension who were enrolled in the renal denervation for resistant hypertension (DENERHTN) trial, 709 (50 percent) were excluded from receiving denervation because a secondary cause of hypertension was identified [<a href="#rid38">38,39</a>]. The most common causes of secondary hypertension are primary aldosteronism and renal artery stenosis, chronic kidney disease, and obstructive sleep apnea  (<a class="graphic graphic_table graphicRef77787" href="/d/graphic/77787.html" rel="external">table 3</a>). Less common causes include pheochromocytoma, Cushing's syndrome, and aortic coarctation.</p><p>All of these disorders are reviewed in detail elsewhere on the appropriate topic reviews. The following discussion will be limited to their association with resistant hypertension.</p><p class="headingAnchor" id="H13"><span class="h3">Clinical clues</span><span class="headingEndMark"> — </span>There are a number of clinical clues suggesting the possible presence of secondary rather than primary hypertension (formerly called "essential" hypertension), one of which is resistant hypertension. Thus, secondary hypertension should be considered in all patients with resistant hypertension. The clinical clues suggesting secondary hypertension are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/3862.html" rel="external">"Evaluation of secondary hypertension"</a>.)</p><p class="headingAnchor" id="H14"><span class="h3">Primary aldosteronism</span><span class="headingEndMark"> — </span>Primary aldosteronism has been reported in approximately 10 to 20 percent of patients with resistant hypertension [<a href="#rid40">40-42</a>]. Otherwise unexplained hypokalemia is the major clue to the presence of primary hyperaldosteronism [<a href="#rid41">41</a>]. However, more than 50 percent of patients with proven primary hyperaldosteronism are normokalemic at presentation. Thus, the absence of hypokalemia does not exclude this disorder. (See  <a class="medical medical_review" href="/d/html/138.html" rel="external">"Diagnosis of primary aldosteronism", section on 'Variable presentation'</a> and  <a class="medical medical_review" href="/d/html/140.html" rel="external">"Pathophysiology and clinical features of primary aldosteronism"</a>.)</p><p>In the largest published experience of 1616 patients with resistant hypertension, 11 percent fulfilled criteria for primary aldosteronism [<a href="#rid40">40</a>]. Among the patients with primary aldosteronism, only 46 percent had hypokalemia.</p><p class="headingAnchor" id="H15"><span class="h3">Renal artery stenosis</span><span class="headingEndMark"> — </span>Renal artery stenosis is a common cause of resistant hypertension and can be due to either atherosclerotic disease or, in younger patients, fibromuscular dysplasia. (See  <a class="medical medical_review" href="/d/html/3825.html" rel="external">"Establishing the diagnosis of renovascular hypertension"</a> and  <a class="medical medical_review" href="/d/html/3874.html" rel="external">"Clinical manifestations and diagnosis of fibromuscular dysplasia"</a>.)</p><p class="headingAnchor" id="H16"><span class="h3">Chronic kidney disease</span><span class="headingEndMark"> — </span>As kidney function declines in patients with chronic kidney disease, there is an increasing need for additional antihypertensive medications [<a href="#rid26">26</a>]. Diuretics play a central role. Diuretics should be pushed until the blood pressure goal is reached or the patient has attained "dry weight," which, in the presence of persistent hypertension, is defined as the weight at which further fluid loss leads to either symptoms (fatigue, orthostatic hypotension) or decreased tissue perfusion as evidenced by an otherwise unexplained elevation in the blood urea nitrogen and/or serum creatinine concentration. (See  <a class="medical medical_review" href="/d/html/3872.html" rel="external">"Overview of hypertension in acute and chronic kidney disease", section on 'Choice of antihypertensive therapy'</a>.)</p><p class="headingAnchor" id="H17"><span class="h3">Obstructive sleep apnea</span><span class="headingEndMark"> — </span>Obstructive sleep apnea is common among patients with resistant hypertension who are referred for sleep studies. In three series of patients with resistant hypertension who were referred for sleep studies, significant obstructive sleep apnea was detected in 71 to 85 percent [<a href="#rid43">43-45</a>] and, in one, was significantly more common than in patients with controlled hypertension (71 versus 38 percent, adjusted odds ratio 4.8, 95% CI 2.0-11.7) [<a href="#rid43">43</a>]. The severity of sleep apnea correlates with the severity of hypertension, and both the incidence and severity of sleep apnea were greater in men than women [<a href="#rid43">43-46</a>].</p><p>Based upon such observations, we suggest screening for obstructive sleep apnea in patients with resistant hypertension who have one or more of the following risk factors: obesity, loud snoring, and/or daytime sleepiness. (See  <a class="medical medical_review" href="/d/html/7706.html" rel="external">"Clinical presentation and diagnosis of obstructive sleep apnea in adults"</a>.)</p><p>The treatment of obstructive sleep apnea with positive airway pressure provides a usually modest antihypertensive benefit among patients with hypertension. The effect in resistant hypertension has not been well-studied. (See  <a class="medical medical_review" href="/d/html/7705.html" rel="external">"Obstructive sleep apnea and cardiovascular disease in adults", section on 'Hypertension'</a>.)</p><p class="headingAnchor" id="H18"><span class="h1">BLOOD PRESSURE MEASUREMENT</span><span class="headingEndMark"> — </span>The diagnosis of resistant hypertension depends upon an accurate measurement of the blood pressure [<a href="#rid26">26</a>]. To avoid falsely high readings, it is particularly important to have the patient sit quietly for three to five minutes before taking the measurement, to use the correct cuff size (the adult large cuff for the majority of patients with resistant hypertension), and to support the arm at heart level during measurement. The blood pressure should be measured in both arms, with the arm with the higher pressure being used to make future measurements.</p><p>These and other components of blood pressure measurement are discussed separately. (See  <a class="medical medical_review" href="/d/html/3879.html" rel="external">"Blood pressure measurement in the diagnosis and management of hypertension in adults"</a>.)</p><p class="headingAnchor" id="H19"><span class="h2">Ambulatory and home blood pressure monitoring</span><span class="headingEndMark"> — </span>As noted above, some patients have pseudoresistant hypertension due to errors in blood pressure measurement or white coat hypertension  (<a class="graphic graphic_algorithm graphicRef127818" href="/d/graphic/127818.html" rel="external">algorithm 1</a>). (See <a class="local">'Apparent, true, and pseudoresistant hypertension'</a> above.)</p><p>Clinical findings that should raise suspicion of white coat hypertension include poorly-controlled office hypertension without evidence of end-organ damage (such as left ventricular hypertrophy on an echocardiogram) or symptoms suggestive of hypoperfusion [<a href="#rid47">47</a>]. On the other hand, true resistant hypertension is likely when the office systolic pressure is ≥180 mmHg and/or the patient has echocardiographic or electrocardiographic evidence of left ventricular hypertrophy [<a href="#rid15">15</a>]. (See  <a class="medical medical_review" href="/d/html/3820.html" rel="external">"Out-of-office blood pressure measurement: Ambulatory and self-measured blood pressure monitoring"</a>.)</p><p>True resistant hypertension can only be distinguished from white coat effected in a treated patient with hypertension by out-of-office blood pressure measurements [<a href="#rid15">15</a>]. This is best accomplished with 24-hour ambulatory monitoring although home and workplace assessments can be utilized if one is confident that the blood pressure is being measured accurately. Ambulatory monitoring or self-measured (home) blood pressure should ideally be attained in all patients with resistant hypertension.</p><p>If out-of-office readings are at or below the desired target while office readings remain elevated, home or office readings may be used to guide medication adjustments. In addition to out-of-office measurements, the acute increase in office blood pressure can be minimized by having a nurse or technician take the blood pressure rather than the doctor  (<a class="graphic graphic_figure graphicRef73781" href="/d/graphic/73781.html" rel="external">figure 1</a>) [<a href="#rid48">48</a>].</p><p>Ambulatory monitoring and self-measured (home) blood pressure are also better predictors than office blood pressure measurements of cardiovascular morbidity (ie, end-organ damage) and mortality in patients with resistant hypertension. (See  <a class="medical medical_review" href="/d/html/3819.html" rel="external">"Treatment of resistant hypertension"</a>.)</p><p class="headingAnchor" id="H20"><span class="h2">Cuff inflation hypertension</span><span class="headingEndMark"> — </span>A possible problem with self-measurement using a sphygmomanometer is that the muscular activity used to inflate the cuff can acutely raise the blood pressure by as much as 12/9 mmHg, an effect called cuff inflation hypertension that dissipates within 5 to 20 seconds (average 7 seconds in one study) [<a href="#rid47">47</a>]. Thus, inflating the cuff to at least 30 mmHg above systolic and then allowing the sphygmomanometer to fall no more than 2 to 3 mmHg per heartbeat is desirable both for accurate measurement and to permit this exertional effect to disappear [<a href="#rid47">47</a>]. This problem can be avoided with automated home blood pressure devices.</p><p class="headingAnchor" id="H21"><span class="h1">OTHER COMPONENTS OF EVALUATION</span><span class="headingEndMark"> — </span>The evaluation of patients with suspected resistant hypertension should confirm true treatment resistance, identify contributing factors including secondary causes of hypertension, and document target-organ damage including retinopathy, left ventricular hypertrophy, and kidney disease [<a href="#rid1">1</a>].</p><p>Pseudoresistance is excluded by an assessment of treatment adherence and the accurate determination of blood pressure. (See <a class="local">'Apparent, true, and pseudoresistant hypertension'</a> above.)</p><p class="headingAnchor" id="H22"><span class="h2">Medical history</span><span class="headingEndMark"> — </span>The medical history should document age of onset, duration, severity, and progression of the hypertension. Current medication use (including herbal and over-the-counter medications) and the response to prior medications should be determined. Patient adherence is established mostly by self-report or by assessing prescription refill rates. The clinician should ask about adverse effects of medications, out-of-pocket costs, and dosing inconvenience, all of which can limit adherence.</p><p>The patient should also be questioned about possible manifestations of secondary causes of hypertension, such as pheochromocytoma and Cushing's syndrome. (See  <a class="medical medical_review" href="/d/html/3862.html" rel="external">"Evaluation of secondary hypertension"</a>.)</p><p class="headingAnchor" id="H23"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>The physical examination should include careful measurement of the blood pressure and funduscopic examination looking for retinopathy. In addition, signs that suggest secondary causes of hypertension may be present. As examples, carotid, abdominal, or femoral bruits suggest atherosclerotic disease and possible renal artery stenosis. Diminished femoral pulses and/or a discrepancy between arm and thigh blood pressures suggest aortic coarctation or significant aortoiliac disease. (See  <a class="medical medical_review" href="/d/html/3862.html" rel="external">"Evaluation of secondary hypertension"</a> and  <a class="medical medical_review" href="/d/html/5760.html" rel="external">"Clinical manifestations and diagnosis of coarctation of the aorta", section on 'Blood pressure and pulses'</a>.)</p><p class="headingAnchor" id="H24"><span class="h2">Laboratory evaluation</span><span class="headingEndMark"> — </span>Laboratory testing in patients with resistant hypertension includes measurement of serum electrolytes, glucose, and creatinine as well as a urinalysis with estimation of proteinuria (eg, urine albumin-to-creatinine ratio).</p><p>Screening for primary aldosteronism is also warranted at the initial visit if possible since, in the largest published experience of 1616 patients with resistant hypertension, 11 percent fulfilled criteria for primary aldosteronism, only 46 percent of whom were hypokalemic [<a href="#rid40">40</a>]. Despite this recommendation, screening for primary aldosteronism is performed in only a small minority of patients with resistant hypertension (2 percent in one large study) [<a href="#rid49">49</a>]. (See <a class="local">'Definitions'</a> above and <a class="local">'Primary aldosteronism'</a> above.)</p><p>Screening for primary aldosteronism begins with a morning measurement of the plasma aldosterone concentration (PAC) and plasma renin activity (PRA) to determine whether the patient has an elevated or high-normal PAC, suppressed PRA, and elevated PAC/PRA ratio. Certain antihypertensive drugs can alter the ratio, some of which should be discontinued prior to testing. If the ratio suggests primary aldosteronism, further evaluation is necessary to confirm the diagnosis. These issues are discussed in detail elsewhere. </p><p>In addition to blood testing, a 24-hour urine collection should be obtained at the time of the blood testing on the patient's usual diet for determination of sodium excretion, creatinine clearance, and aldosterone excretion. Urinary sodium excretion permits estimation of dietary sodium intake unless the patient has been recently (within the past two weeks) started on a diuretic or there has been a recent dose increase.</p><p>Patients with resistant hypertension should be evaluated for pheochromocytoma if they have suggestive manifestations such as episodic hypertension, palpitations and/or diaphoresis, or tremor. (See  <a class="medical medical_review" href="/d/html/130.html" rel="external">"Clinical presentation and diagnosis of pheochromocytoma"</a>.)</p><p class="headingAnchor" id="H25"><span class="h2">Noninvasive imaging</span><span class="headingEndMark"> — </span>Most patients with resistant hypertension should undergo noninvasive imaging for renal artery stenosis. This is particularly important in patients with known atherosclerotic disease in other vascular beds, including peripheral artery disease, coronary artery disease or cerebrovascular disease, an abdominal bruit, a rise in serum creatinine after initiation of an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB), or onset of hypertension at a young age, which could represent fibromuscular dysplasia.</p><p>Among patients with resistant hypertension who have none of these risk factors, we delay screening for renovascular disease until the remainder of the evaluation for resistant hypertension is negative. The preferred methods of screening are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/3825.html" rel="external">"Establishing the diagnosis of renovascular hypertension"</a>.)</p><p>Because of low specificity, imaging studies should not be performed to screen for adrenal adenomas in the absence of biochemical evidence of hormonally active tumors. (See  <a class="medical medical_review" href="/d/html/137.html" rel="external">"Clinical presentation and evaluation of adrenocortical tumors"</a>.)</p><p class="headingAnchor" id="H2452822837"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109601.html" rel="external">"Society guideline links: Hypertension in adults"</a>.)</p><p class="headingAnchor" id="H26"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph utd-adt-cnt utd-adt-pathwys">●</span>Resistant hypertension is defined as blood pressure that remains above goal in spite of concurrent use of three antihypertensive agents of different classes or as blood pressure that is controlled with four or more medications. One of the medications should be a diuretic, if tolerated, and all should be prescribed at maximum recommended (or maximally tolerated) antihypertensive doses. Approximately 3 percent of patients with resistant hypertension cannot be controlled (called refractory hypertension) despite maximal medical therapy. Among patients with apparent resistance, true resistant hypertension should be distinguished from pseudoresistance  (<a class="graphic graphic_algorithm graphicRef127818" href="/d/graphic/127818.html" rel="external">algorithm 1</a>). (See <a class="local">'Resistant hypertension'</a> above and <a class="local">'Refractory hypertension'</a> above.) <span class="utd-adt-cnt utd-adt-pathwys utd-content-127445">(Related Pathway(s):  <a class="utd-content-127445" href="/pathway/127445?topicRef=3818&amp;source=see_link">Evaluation of adults with apparent resistant hypertension</a>.)</span></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pseudoresistant hypertension refers to hypertension resulting from inaccurate measurement of blood pressure (eg, use of an inappropriately small blood pressure cuff), poor adherence to antihypertensive therapy, suboptimal antihypertensive therapy, poor adherence to lifestyle and dietary approaches to lower blood pressure, or white coat effect. (See <a class="local">'Apparent, true, and pseudoresistant hypertension'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Careful blood pressure measurement technique is essential to establish an accurate diagnosis of resistant hypertension. Out-of-office blood pressure measurements are required to exclude white coat effects. (See <a class="local">'Blood pressure measurement'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Potentially reversible factors that contribute to resistant hypertension include suboptimal therapy, lifestyle and diet, medications and herbal preparations that can raise the blood pressure, and secondary causes of hypertension. (See <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Most patients with resistant hypertension should be evaluated for the possible presence of primary aldosteronism, renal artery stenosis, chronic kidney disease, and obstructive sleep apnea. Less common identifiable causes of resistant hypertension include pheochromocytoma, Cushing's syndrome, and aortic coarctation. Screening for one of these disorders should only be performed if the patient has suggestive manifestations. (See <a class="local">'Secondary causes of hypertension'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The evaluation should include measurement of serum electrolytes, glucose, urea nitrogen and creatinine, and a urinalysis. Morning plasma aldosterone concentration (PAC) and plasma renin activity (PRA) should be measured to screen for primary aldosteronism. A 24-hour urine should be obtained for determination of sodium excretion, creatinine clearance, and aldosterone excretion. (See <a class="local">'Laboratory evaluation'</a> above.)</p><p></p><p class="headingAnchor" id="H2381965325"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges David A Calhoun, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Carey RM, Calhoun DA, Bakris GL, et al. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. Hypertension 2018; 72:e53.</a></li><li><a class="nounderline abstract_t">Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018; 71:e13.</a></li><li><a class="nounderline abstract_t">Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 39:3021.</a></li><li><a class="nounderline abstract_t">Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) 2002; 4:393.</a></li><li><a class="nounderline abstract_t">Dudenbostel T, Siddiqui M, Oparil S, Calhoun DA. Refractory Hypertension: A Novel Phenotype of Antihypertensive Treatment Failure. Hypertension 2016; 67:1085.</a></li><li><a class="nounderline abstract_t">Dudenbostel T, Acelajado MC, Pisoni R, et al. Refractory Hypertension: Evidence of Heightened Sympathetic Activity as a Cause of Antihypertensive Treatment Failure. Hypertension 2015; 66:126.</a></li><li><a class="nounderline abstract_t">Egan BM, Zhao Y, Li J, et al. Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network. Hypertension 2013; 62:691.</a></li><li><a class="nounderline abstract_t">Calhoun DA. Apparent and true resistant hypertension: why not the same? J Am Soc Hypertens 2013; 7:509.</a></li><li><a class="nounderline abstract_t">Grigoryan L, Pavlik VN, Hyman DJ. Characteristics, drug combinations and dosages of primary care patients with uncontrolled ambulatory blood pressure and high medication adherence. J Am Soc Hypertens 2013; 7:471.</a></li><li><a class="nounderline abstract_t">de Jager RL, de Beus E, Beeftink MM, et al. Impact of Medication Adherence on the Effect of Renal Denervation: The SYMPATHY Trial. Hypertension 2017; 69:678.</a></li><li><a class="nounderline abstract_t">Jung O, Gechter JL, Wunder C, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens 2013; 31:766.</a></li><li><a class="nounderline abstract_t">Tomaszewski M, White C, Patel P, et al. High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart 2014; 100:855.</a></li><li><a class="nounderline abstract_t">Siddiqui M, Judd EK, Dudenbostel T, et al. Antihypertensive Medication Adherence and Confirmation of True Refractory Hypertension. Hypertension 2020; 75:510.</a></li><li><a class="nounderline abstract_t">de la Sierra A, Segura J, Banegas JR, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011; 57:898.</a></li><li><a class="nounderline abstract_t">Muxfeldt ES, Bloch KV, Nogueira Ada R, Salles GF. True resistant hypertension: is it possible to be recognized in the office? Am J Hypertens 2005; 18:1534.</a></li><li><a class="nounderline abstract_t">Redon J, Campos C, Narciso ML, et al. Prognostic value of ambulatory blood pressure monitoring in refractory hypertension: a prospective study. Hypertension 1998; 31:712.</a></li><li><a class="nounderline abstract_t">de la Sierra A, Banegas JR, Oliveras A, et al. Clinical differences between resistant hypertensives and patients treated and controlled with three or less drugs. J Hypertens 2012; 30:1211.</a></li><li><a class="nounderline abstract_t">Pierdomenico SD, Lapenna D, Bucci A, et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens 2005; 18:1422.</a></li><li><a class="nounderline abstract_t">Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension 2011; 57:1076.</a></li><li><a class="nounderline abstract_t">Muxfeldt ES, Nogueira Ada R, Salles GF, Bloch KV. Demographic and clinical characteristics of hypertensive patients in the internal medicine outpatient clinic of a university hospital in Rio de Janeiro. Sao Paulo Med J 2004; 122:87.</a></li><li><a class="nounderline abstract_t">Sim JJ, Bhandari SK, Shi J, et al. Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system. Mayo Clin Proc 2013; 88:1099.</a></li><li><a class="nounderline abstract_t">Egan BM, Zhao Y, Rehman SU, et al. Treatment resistant hypertension in a community-based practice network (abstract). J Clin Hypertens (Greenwich) 2009; OR-12:A6.</a></li><li><a class="nounderline abstract_t">Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012; 125:1635.</a></li><li><a class="nounderline abstract_t">Ebinger JE, Gluckman TJ, Magraner J, et al. Characterization of Individuals With Apparent Resistant Hypertension Using Contemporary Guidelines: Insights From CV-QUIC. Hypertension 2023; 80:1845.</a></li><li><a class="nounderline abstract_t">Ma J, Lee KV, Stafford RS. Changes in antihypertensive prescribing during US outpatient visits for uncomplicated hypertension between 1993 and 2004. Hypertension 2006; 48:846.</a></li><li><a class="nounderline abstract_t">Braam B, Taler SJ, Rahman M, et al. Recognition and Management of Resistant Hypertension. Clin J Am Soc Nephrol 2017; 12:524.</a></li><li><a class="nounderline abstract_t">Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998; 339:1957.</a></li><li><a class="nounderline abstract_t">Amar J, Chamontin B, Genes N, et al. Why is hypertension so frequently uncontrolled in secondary prevention? J Hypertens 2003; 21:1199.</a></li><li><a class="nounderline abstract_t">Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens 2014; 32:3.</a></li><li><a class="nounderline abstract_t">Pimenta E, Gaddam KK, Oparil S, et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension 2009; 54:475.</a></li><li><a class="nounderline abstract_t">Chan CC, Reid CM, Aw TJ, et al. Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis. J Hypertens 2009; 27:2332.</a></li><li><a class="nounderline abstract_t">Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105.</a></li><li><a class="nounderline abstract_t">Setaro JF, Black HR. Refractory hypertension. N Engl J Med 1992; 327:543.</a></li><li><a class="nounderline abstract_t">Fugh-Berman A. Herb-drug interactions. Lancet 2000; 355:134.</a></li><li><a class="nounderline abstract_t">Licht CM, de Geus EJ, Seldenrijk A, et al. Depression is associated with decreased blood pressure, but antidepressant use increases the risk for hypertension. Hypertension 2009; 53:631.</a></li><li><a class="nounderline abstract_t">Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med 2008; 168:1159.</a></li><li><a class="nounderline abstract_t">Taler SJ, Textor SC, Augustine JE. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension 2002; 39:982.</a></li><li><a class="nounderline abstract_t">Azizi M, Sapoval M, Gosse P, et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet 2015; 385:1957.</a></li><li><a class="nounderline abstract_t">Stergiou GS, Myers MG, Reid JL, et al. Setting-up a blood pressure and vascular protection clinic: requirements of the European Society of Hypertension. J Hypertens 2010; 28:1780.</a></li><li><a class="nounderline abstract_t">Douma S, Petidis K, Doumas M, et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 2008; 371:1921.</a></li><li><a class="nounderline abstract_t">Calhoun DA, Nishizaka MK, Zaman MA, et al. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002; 40:892.</a></li><li><a class="nounderline abstract_t">Eide IK, Torjesen PA, Drolsum A, et al. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 2004; 22:2217.</a></li><li><a class="nounderline abstract_t">Gonçalves SC, Martinez D, Gus M, et al. Obstructive sleep apnea and resistant hypertension: a case-control study. Chest 2007; 132:1858.</a></li><li><a class="nounderline abstract_t">Logan AG, Perlikowski SM, Mente A, et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens 2001; 19:2271.</a></li><li><a class="nounderline abstract_t">Pratt-Ubunama MN, Nishizaka MK, Boedefeld RL, et al. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest 2007; 131:453.</a></li><li><a class="nounderline abstract_t">Parati G, Lombardi C, Hedner J, et al. Recommendations for the management of patients with obstructive sleep apnoea and hypertension. Eur Respir J 2013; 41:523.</a></li><li><a class="nounderline abstract_t">Mejia AD, Egan BM, Schork NJ, Zweifler AJ. Artefacts in measurement of blood pressure and lack of target organ involvement in the assessment of patients with treatment-resistant hypertension. Ann Intern Med 1990; 112:270.</a></li><li><a class="nounderline abstract_t">Mancia G, Parati G, Pomidossi G, et al. Alerting reaction and rise in blood pressure during measurement by physician and nurse. Hypertension 1987; 9:209.</a></li><li><a class="nounderline abstract_t">Jaffe G, Gray Z, Krishnan G, et al. Screening Rates for Primary Aldosteronism in Resistant Hypertension: A Cohort Study. Hypertension 2020; 75:650.</a></li></ol></div><div id="topicVersionRevision">Topic 3818 Version 42.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30354828" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29133356" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30165516" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : 2018 ESC/ESH Guidelines for the management of arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12461301" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27091893" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Refractory Hypertension: A Novel Phenotype of Antihypertensive Treatment Failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25987662" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Refractory Hypertension: Evidence of Heightened Sympathetic Activity as a Cause of Antihypertensive Treatment Failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23918752" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24035315" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Apparent and true resistant hypertension: why not the same?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23890931" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Characteristics, drug combinations and dosages of primary care patients with uncontrolled ambulatory blood pressure and high medication adherence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28264922" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Impact of Medication Adherence on the Effect of Renal Denervation: The SYMPATHY Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23337469" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Resistant hypertension? Assessment of adherence by toxicological urine analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24694797" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31813346" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Antihypertensive Medication Adherence and Confirmation of True Refractory Hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21444835" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16364821" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : True resistant hypertension: is it possible to be recognized in the office?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9461245" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Prognostic value of ambulatory blood pressure monitoring in refractory hypertension: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22525201" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Clinical differences between resistant hypertensives and patients treated and controlled with three or less drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16280275" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21502568" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Prevalence of resistant hypertension in the United States, 2003-2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15448805" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Demographic and clinical characteristics of hypertensive patients in the internal medicine outpatient clinic of a university hospital in Rio de Janeiro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24079679" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Treatment resistant hypertension in a community-based practice network (abstract)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22379110" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Incidence and prognosis of resistant hypertension in hypertensive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37357771" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Characterization of Individuals With Apparent Resistant Hypertension Using Contemporary Guidelines: Insights From CV-QUIC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16982967" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Changes in antihypertensive prescribing during US outpatient visits for uncomplicated hypertension between 1993 and 2004.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27895136" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Recognition and Management of Resistant Hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9869666" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Inadequate management of blood pressure in a hypertensive population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12777958" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Why is hypertension so frequently uncontrolled in secondary prevention?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24270181" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19620517" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19887957" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17563527" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1635569" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Refractory hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10675182" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Herb-drug interactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19237679" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Depression is associated with decreased blood pressure, but antidepressant use increases the risk for hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18541823" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12019280" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Resistant hypertension: comparing hemodynamic management to specialist care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25631070" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20647863" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Setting-up a blood pressure and vascular protection clinic: requirements of the European Society of Hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18539224" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12468575" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Hyperaldosteronism among black and white subjects with resistant hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15480108" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Low-renin status in therapy-resistant hypertension: a clue to efficient treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18079220" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Obstructive sleep apnea and resistant hypertension: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11725173" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : High prevalence of unrecognized sleep apnoea in drug-resistant hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17296647" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23397300" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Recommendations for the management of patients with obstructive sleep apnoea and hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2297205" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Artefacts in measurement of blood pressure and lack of target organ involvement in the assessment of patients with treatment-resistant hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3818018" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Alerting reaction and rise in blood pressure during measurement by physician and nurse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32008436" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Screening Rates for Primary Aldosteronism in Resistant Hypertension: A Cohort Study.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
